Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents is a research paper published in Journal of Clinical Epidemiology (2011). On theSindex it has a DataRank of 0.470. It has been cited 22 times.
ObjectiveTo assess whether there are preferences and avoidances for specific comparisons in a clinical trials agenda.Study design and settingWe tested for homophily (preference to compare agents against others in the same class) and co-occurrence (preference or avoidance of specific head-to-head comparisons) in the randomized trials agenda of antifungal agents. We searched MEDLINE and Cochrane Library databases for English language randomized trials evaluating systemic antifungals against Candida or Aspergillus in adults. We extracted data on compared regimens, sample size, publication year, indication (treatment/prophylaxis), and underlying disease.ResultsOne hundred forty-four trials (74 treatments, 70 prophylaxes) were found (n=27,497 patients). Among polyene and azole groups, agents were compared within the same class more often than across classes (homophily test PConclusionsTrial networks for antifungals show that specific comparisons are preferred and others avoided, generating a potentially biased clinical research agenda.
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Base Score Contribution
0.470
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →DataRank blends this paper's own citation count with the influence of the papers that cite it. Here, roughly 100% comes from its base citations and 0% from the citation network.
Citers are pulled from OpenAlex sorted by cited_by_count:descand capped per paper, so when the cap binds we keep the highest-signal references and the score is reproducible across reruns.